Intezyne acquires Niki Pharma

Intezyne Technologies has acquired Niiki Pharma. The acquisition gives Intezyne a Phase 2 asset being developed for non-pancreatic endocrine tumor. Niiki Pharma's GRP78 suppressor (NKP-1339), which has recently entered Phase 2 has the potential to enhance the treatment of neuroendocrine tumors and other tumor types. Currently there are no anti-tumor therapies that are approved for this specific type of cancer.